204387-55-3

Basic information

• Product Name: (R)-2-Methylpyrrolidine tosylate
• Synonyms: (R)-2-METHYL-PYRROLIDINE TOSYLATE;(R)-2-Methylpyrrolidine 4-methylphenylsulphonate;(2R)-2-Methylpyrrolidine toluene-4-sulphonate;(R)-2-Methylpyrrolidine p-toluenesulfonate, 97%;(2R)-2-Methylpyrrolidine tosylate;(R)-2-Methylpyrrolidine 4-methylbenzenesulfonate;(2R)-2-Methylpyrrolidine toluene-4-sulfonate
• CAS NO: 204387-55-3
• Molecular Formula: C12H19NO3S
• Molecular Weight: 257.35
• Product Categories: Heterocyclic Series
• Mol File: 204387-55-3.mol

Chemical Properties

• Boiling Point: 423.9 °C at 760 mmHg
• Flash Point: 210.2 °C
• Appearance: /
• Vapor Pressure: 6.09E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-Methylpyrrolidine tosylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-Methylpyrrolidine tosylate(204387-55-3)
• EPA Substance Registry System: (R)-2-Methylpyrrolidine tosylate(204387-55-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 204387-55-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(R)-2-Methylpyrrolidine tosylate is used as a reagent for facilitating various chemical reactions in organic synthesis. Its tosylate group, with its good leaving properties, makes it a valuable component in the formation of new chemical bonds and the synthesis of complex molecules.
Used in Research Laboratories:
(R)-2-Methylpyrrolidine tosylate is used as a research tool in academic and industrial research settings. Its unique structure and properties allow scientists to explore its potential applications and interactions with other molecules, contributing to the advancement of chemical knowledge and the development of new compounds and materials.

InChI:InChI=1/C7H8O3S.C5H11N/c1-6-2-4-7(5-3-6)11(8,9)10;1-5-3-2-4-6-5/h2-5H,1H3,(H,8,9,10);5-6H,2-4H2,1H3/t;5-/m.1/s1

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 765-38-8 (R)-(-)-2-methylpyrrolidine 
• 765-38-8 (S)-2-methylpyrrolidine 
• 157007-54-0 2-(R)-methylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 137496-71-0 2-methylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 132482-09-8 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}-pyrrolidine-1-carboxylate 
• 132482-10-1 (R)-1-<(1,1-dimethylethoxy)carbonyl>-2-pyrrolidinemethanolmethanesulfonate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 37784-17-1 N-(tert-butoxycarbonyl)-D-proline 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 59378-81-3 1-(tert-butoxycarbonyl)prolin-2R-ol 

Relevant articles and documents

Synthesis and evaluation of in vivo anti-hypothermic effect of all stereoisomers of the thyrotropin-releasing hormone mimetic: Rovatirelin Hydrate

We discovered the orally active thyrotropin-releasing hormone (TRH) mimetic: (4S,5S)-5-methyl-N-{(2S)-1-[(2R)-2-methylpyrrolidin-1-yl]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide 1 (rovatirelin). The central nervous system (CNS) effect of rovatirelin after intravenous (iv) administration is 100-fold higher than that of TRH. As 1 has four asymmetric carbons in its molecule, there are 16 stereoisomers. We synthesized and evaluated the anti-hypothermic effect of all stereoisomers of 1, which has the (4S),(5S),(2S),(2R) configuration from the N-terminus to the C-terminus, in order to clarify the structure?activity relationship (SAR) of stereoisomers. The (4R),(5R),(2R),(2S)-isomer 16 did not show any anti-hypothermic effect. Only the (4S),(5S),(2S),(2S)-isomer 10, which has the (2S)-2-methylpyrrolidine moiety at the C-terminus showed the anti-hypothermic effect similar to 1. Stereoisomers, which have the (5R) configuration of the oxazolidinone at the N-terminus and the (2R) configuration at the middle-part, showed a much lower anti-hypothermic effect than that of 1. On the other hand, stereoisomers, which have the (4R) configuration of the oxazolidinone at the N-terminus or the (2S) configuration of the C-terminus, have little influence on the anti-hypothermic effect.

Process for producing 4-thiazolylmethyl derivative

A process for the production of 4-thiazolylmethyl derivatives are provided. A process for the production of the compound represented by the formula (I): wherein R1is hydrogen or halogen and Hal is halogen, which comprises reacting 4-methylthiazole with N-halosuccinimide in a solvent in the presence of a radical initiator.

Peptide derivatives having thiazolyl-alanine residue

A peptide derivation of the formula (I) or its pharmaceutically acceptable salt or hydrate thereof is disclosed. These compounds have superior ability over thyroid stimulating hormone (TRH) and its derivatives to activate the central nervous system, such as, for example, sustained acetylcholine releasing action, anti-reserpine action and locomotor increment.